FierceBiotechOriginal article
{"a":[{"_":"Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope","$":{"href":"/biotech/connect-biopharma-missing-asthma-primary-endpoint-sends-investors-spiraling-about-copd","hreflang":"en"}}]}
Phase 2negativeIL-4/IL-13 blockerDupixentNegative
AI Analysis
Summary
Connect Biopharma's IL-4/IL-13 blocker failed to meet the primary endpoint in a phase 2 asthma study, missing its goal to challenge Dupixent's market position in the indication.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Missed primary endpoint in phase 2 asthma trial
Importance:7/10
Sentiment:
-0.70
phase 2 failureasthmaIL-4/IL-13 inhibitorclinical trialcompetitive threat
Related Companies
Read the original article
Published by FierceBiotech on September 15, 2026 10:00 AM